RegeneRx Biopharmaceuticals, Inc. has expanded its license to ReGenTree, LLC for RGN-259 in North American from solely the US to the US and Canada. The license expansion was negotiated pursuant to a term sheet that was previously announced by RegeneRx in its most recent Form 10-K.
RegeneRx previously received a payment from ReGenTree of $250,000 under the term sheet, which is the license fee for the expanded territory. The US license between the two companies has been amended to include Canada, and the Canadian territory will be subject to the same royalty structure as currently exists.
ReGenTree has notified the company that it expects to report data from the recently completed dry eye trial the week of May 2nd.
RegeneRx is focused on the development of novel therapeutic peptides, including Thymosin beta 4 and its constituent fragments, for tissue and organ protection, repair and regeneration.
ReGenTree, LLC is a US joint venture company owned by G-treeBNT Co., Ltd., a bio venture company in Korea and RegeneRx Biopharmaceuticals, Inc., a clinical stage drug development company in the US.